Tandem occlusions in acute ischemic stroke – impact of antithrombotic medication and complementary heparin on clinical outcome and stent patency. (14th January 2020)

• Record Type: Journal Article
• Authors: Neuberger, Ulf; Moteva, Konstantina; Vollherbst, Dominik F; Schönenberger, Silvia; Reiff, Tilman; Ringleb, Peter Arthur; Bendszus, Martin; Pfaff, Johannes Alex Rolf; Möhlenbruch, Markus
• Is Part Of: Journal of neurointerventional surgery. Volume 12:Number 11(2020)
• Page Start: 1088
• Page End: 1093
• Publication Date: 2020-01-14
• Subjects: intervention -- stroke -- thrombectomy -- hemorrhage -- stent; Nervous system -- Surgery -- Periodicals; Cerebrovascular disease -- Surgery -- Periodicals; 617.48
• DOI: 10.1136/neurintsurg-2019-015596
• Languages: English
• ISSNs: 1759-8478

Abstract

Abstract : Background and purpose: Mechanical thrombectomy (MT) and acute carotid stenting (ACS) of patients with acute ischemic stroke due to tandem occlusions (TO) of the anterior circulation was proven to be safe and effective, but the implications of periprocedural antithrombotic medications are only known to a limited extent. Methods: We conducted a retrospective analysis of 162 consecutive patients who presented with TO and were treated with MT and ACS in our center. Patients initially either received dual antiplatelet therapy (DAT) or tirofiban periprocedurally. Some patients were also treated with unfractionated heparin. The frequency of intracranial hemorrhages (ICH), as well as the impact on clinical outcome and stent patency of different medical regimes, were evaluated using univariate tests and adjusted multivariate logistic regressions. Results: Patients who received supportive treatment with heparin had significantly higher occurrences of any (OR, 2.46; 95% CI, 1.15 to 5.28) and symptomatic ICH (OR, 3.71; 95% CI, 1.18 to 14.95). Additionally, these patients were less likely to have a moderate clinical outcome after 90 days (modified Rankin scale 0–3; OR, 0.33; 95% CI, 0.15 to 0.72), but were more likely to have a fatal outcome after 90 days (OR, 2.84; 95% CI 1.10 to 7.31). These findings persisted in patients who received both DAT and heparin, but not for patients who received both tirofiban and heparin. Conclusion: Supportive administration of heparin in patients with TO and treatment with MT and ACS should be carefully considered, especially in patients who primarily receive DAT.